New Drug for Skin Cancer Approved

There seems to be some good news for people suffering from advanced basal cell carcinoma as the drug Erivedge has been approved by the FDA to treat this form of skin cancer. Developed by Roche Holding AG in the USA, this drug with the generic name vismodegib was passed by the FDA thought its priority fast-track program, where it only takes six months to review drugs that show promise of major advances in treatment.

Basal cell carcinoma is a slow growing and painless cancer that starts in the epidermis or upper layer of the skin, usually in areas that have been regularly exposed to the sun or UV light.  Erivedge works by inhibiting the Hedgehog pathway, and is a once a day oral medication. The Hedgehog pathway has been found to be active in most basal cell cancers, but only in a few normal tissues such as hair follicles.

 

Switch to our mobile site